191results about How to "Maximum efficacy" patented technology

Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion.

Devices that include multi-reservoir infusion devices and systems for dispensing compositions for the treatment of subjects with an amylin agonist (e.g., the amylin agonist analog, pramlintide), wherein amylin agonists are administered in certain differential bolus and basal ratios to an administered insulin, as well as methods, compositions, and kits and articles of manufacture comprising said compositions for use in the treatment of responsive patients with an amylin and an insulin in ratios thereof that are distinct for bolus and basal administration.

Provided is a compound having a superior acid secretion suppressive action, which shows an antiulcer activity and the like.A compound represented by the formula (I) or a salt thereof:wherein ring A is a saturated or unsaturated 5-membered heterocycle containing, as a ring-constituting atom besides carbon atoms, at least one heteroatom selected from a nitrogen atom, an oxygen atom and a sulfur atom, the ring-constituting atoms X1 and X2 are the same or different and each is C or N, the ring-constituting atoms X3 and X4 are the same or different and each is C, N, 0 or S (provided that a pyrrole ring wherein X1 is N is excluded from ring A), and when the ring-constituting atom X3 or X4 is C or N, each ring-constituting atom optionally has substituent(s) selected from an optionally substituted alkyl, an acyl, an optionally substituted hydroxy, an optionally substituted mercapto, an optionally substituted amino, a halogen, a cyano and a nitro;R1 and R2 are each a cyclic group optionally having substituent(s); R3 and R4 are each H or alkyl, or R3 and R4 form, together with the adjacent N, an nitrogen-containing heterocycle; and Y is a spacer.

Provided are a fusion protein of Exendin-4 and its analog, the preparation method and use thereof. The fusion protein is obtained by fusing of Exendin-4 or its analog to Fc region of human IgG2 via a linking peptide, which has the better stability and prolonged serum half-life, and can be used for treating diabetes and obesity.

The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce apoptosis of the target cell. There is also provided methods of and pharmaceutical compositions for apoptosis induction and uses thereof.

Provided are a fusion protein of Exendin-4 and its analog, the preparation method and use thereof. The fusion protein is obtained by fusing of Exendin-4 or its analog to Fc region of human IgG2 via a linking peptide, which has the better stability and prolonged serum half-life, and can be used for treating diabetes and obesity.

The present invention relates to an herbal composition which is non-alcoholic, non-sedating and non-freezing in nature for the treatment of chronic respiratory disorders such as cold, cough, allergic asthma, seasonal allergic rhinitis, pharyngitis, laryngitis and the like and a process for preparing the same. The process comprises procuring, cleaning, grading of specified herbal plants per the standard specification, disintegrating and pulverizing separately to form coarse powder, then macerating individual powders separately with aqueous solution of preservatives, then extracting, filtering, concentrating and spray drying to make dry extract powder or semisolid soft extract. Further dissolving each of the extracts separately in aqueous solution containing preservatives and then allowing to maturate after mixing. Then adding filtered extracts to the sugar syrup containing preservatives, glycerin and appropriate excipients to obtain a homogenous cough syrup.

Systems and methods are provided for determining optimized settings for a closed-loop stimulation system based on analyzing a phase response curve measured from electrophysiological activity, such as electrical nerve activity or electrical muscle activity. The slope of the phase response curve is computed and used to determine a phase window during which phasic burst stimulation should be provided to achieve a desired effect on oscillations in the subject. When the slope of the phase response curve is positive, a phasic burst stimulation applied during the phase window will decrease synchrony of the oscillations. When the slope of the phase response curve is negative, a phasic burst stimulation applied during the phase window will increase synchrony of the oscillations.

The present invention provides 5-membered heterocycle compounds represented by the following general formula (I):The present compounds have a superior acid secretion inhibitory effect, and shows an antiulcer activity and the like.

The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.